Albireo Pharma (NASDAQ:ALBO) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Volatility and Risk
Albireo Pharma has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Earnings and Valuation
This table compares Albireo Pharma and Anchiano Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Albireo Pharma | $9.64 million | 59.55 | $-62,720,000.00 | ($5.04) | -5.93 |
| Anchiano Therapeutics | N/A | N/A | $-27,120,000.00 | ($3.46) | -5.74 |
Anchiano Therapeutics has lower revenue, but higher earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Albireo Pharma and Anchiano Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Albireo Pharma | -751.53% | -71.22% | -42.91% |
| Anchiano Therapeutics | N/A | 36.08% | 27.40% |
Analyst Ratings
This is a breakdown of recent recommendations for Albireo Pharma and Anchiano Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Albireo Pharma | 0 | 0 | 8 | 0 | 3.00 |
| Anchiano Therapeutics | 0 | 0 | 0 | 0 | N/A |
Albireo Pharma currently has a consensus target price of $72.00, indicating a potential upside of 140.72%. Given Albireo Pharma's higher probable upside, equities analysts clearly believe Albireo Pharma is more favorable than Anchiano Therapeutics.
Insider and Institutional Ownership
85.7% of Albireo Pharma shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Anchiano Therapeutics beats Albireo Pharma on 7 of the 12 factors compared between the two stocks.
